These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38925641)

  • 1. Generating pathways to domestically sourced plasma-derived medicinal products: Report from a workshop by the International Plasma and Fractionation Association and the Working Party on Global Blood Safety of the International Society of Blood Transfusion.
    Farrugia A; Perry R; Rossi F; von Bonsdorff L; Bowie G; Faber JC; Omarjee JH; Epstein J; White J
    Vox Sang; 2024 Sep; 119(9):1012-1020. PubMed ID: 38925641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stepwise access to safe plasma proteins in resource-constrained countries: Local production and pathways to fractionation-Report of an International Society of Blood Transfusion Workshop.
    Burnouf T; Epstein J; Faber JC; Smid M
    Vox Sang; 2022 Jun; 117(6):789-795. PubMed ID: 35262936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low- and middle-income countries.
    Burnouf T; Epstein J; Faber JC; Smid WM;
    Vox Sang; 2024 Feb; 119(2):102-109. PubMed ID: 37872819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dynamics of contract plasma fractionation.
    Farrugia A; Scaramuccia D
    Biologicals; 2017 Mar; 46():159-167. PubMed ID: 28236560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges associated with access to plasma-derived medicinal products in low middle-income and low-income countries.
    El Ekiaby M; Diop S; Gouider E; Moftah F
    Vox Sang; 2024 Feb; 119(2):166-170. PubMed ID: 38050721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for supporting stepwise access to safe plasma proteins through local production in low- and middle-income countries: A commentary of an international workshop.
    Burnouf T; Epstein J; Faber JC; Tayou Tagny C; Somuah D; Smid WM
    Biologicals; 2022 Sep; 79():27-30. PubMed ID: 36050213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Navigating the Asia-Pacific region plasma therapies landscape: Insights from the 2023 Asia-Pacific Plasma Leaders' Network meetings.
    Bhatnagar S; Burnouf T; Prevot J; Faber JC; Büechel R; Maryuningsih YS; Khanh BQ; Mai NT; Nakanishi H; Kataoka M
    Vox Sang; 2024 Nov; 119(11):1207-1213. PubMed ID: 39159943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma is a strategic resource.
    Strengers PF; Klein HG
    Transfusion; 2016 Dec; 56(12):3133-3137. PubMed ID: 27861951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges for Plasma-Derived Medicinal Products.
    Strengers PFW
    Transfus Med Hemother; 2023 Apr; 50(2):116-122. PubMed ID: 37066053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Plasma fractionation in the world: current status].
    Burnouf T
    Transfus Clin Biol; 2007 May; 14(1):41-50. PubMed ID: 17499539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production and Quality Requirements of Human Platelet Lysate: A Position Statement from the Working Party on Cellular Therapies of the International Society of Blood Transfusion.
    Schallmoser K; Henschler R; Gabriel C; Koh MBC; Burnouf T
    Trends Biotechnol; 2020 Jan; 38(1):13-23. PubMed ID: 31326128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of regulatory frameworks on the national lot release of plasma-derived medicinal products in Korea.
    Seong SK; Kim YH; Choi Y; Koh HJ; Kim SJ; Kim MJ; Choi CW
    Biologicals; 2024 May; 86():101768. PubMed ID: 38733709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of plasma for fractionation donated in the United Kingdom, with respect to variant Creutzfeldt-Jakob disease.
    Thomas S; Roberts B; Domanović D; Kramer K; Klochkov D; Sivasubramaniyam S; Miloslavich D; Plançon JP; Rossi F; Misztela D; Kirkpatrick L; Miflin G; Birchall J; McLintock L; Knight R
    Vox Sang; 2023 May; 118(5):345-353. PubMed ID: 36880992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines.
    Cheraghali AM; Aboofazeli R
    Transfus Med; 2009 Dec; 19(6):363-8. PubMed ID: 19778319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International movement of plasma and plasma contracting.
    Farrugia A
    Dev Biol (Basel); 2005; 120():85-96. PubMed ID: 16050160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Workshop on the clinical significance of red blood cell alloantibodies organized by the Working Party on Immunohaematology of the International Society of Blood Transfusion.
    Peyrard T
    Immunohematology; 2019 Sep; 35(3):105-107. PubMed ID: 31621369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma fractionation, a useful means to improve national transfusion system and blood safety: Iran experience.
    Cheraghali AM; Abolghasemi H
    Haemophilia; 2009 Mar; 15(2):487-93. PubMed ID: 19347989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. “Go no Go” in plasma fractionation in the world’s emerging economies: still a question asked 70 years after the COHN process was developed!
    Burnouf T; Seghatchian J
    Transfus Apher Sci; 2014 Oct; 51(2):113-9. PubMed ID: 25457750
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.